Inclusion Criteria:
- Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at Screening
- Meets the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at
Screening
- Active plaque psoriatic skin lesion(s) or documented medical history of plaque
psoriasis (PsO) at Screening
- Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and
Day 1
- Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening
- Must have completed the week 52 treatment for the optional open-label long-term
extension period
Exclusion Criteria:
- Nonplaque psoriasis at Screening or Day 1
- Other autoimmune condition such as systemic lupus erythematous, mixed connective
tissue disease, multiple sclerosis, or vasculitis
- History of or current inflammatory joint disease other than PsA (e.g., gout, reactive
arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease)
- Active fibromyalgia
- Received an approved or investigational biologic therapy for the treatment of PsA or
PsO
Other protocol-defined inclusion/exclusion criteria apply
Active, Not Recruiting
